Psilocybin for clinical indications: A scoping review.

Psilocybin pain management psychedelic medicine scoping review

Journal

Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828

Informations de publication

Date de publication:
13 Aug 2024
Historique:
medline: 13 8 2024
pubmed: 13 8 2024
entrez: 13 8 2024
Statut: aheadofprint

Résumé

Psychedelic drugs have been of interest in medicine since the early 1950s. There has recently been a resurgence of interest in psychedelics. The objective of this study is to determine the extent of the available literature on psilocybin for medical indications including the designs used, study characteristics, indications studied, doses, and authors' conclusions. We identify areas for further study where there are research gaps. We conducted a systematic scoping review of clinical indications for psilocybin, encompassing psychiatric and medical conditions. We systematically searched Medline and Embase using keywords related to psilocybin. We reviewed titles and texts in duplicate using Covidence software. We extracted data individually in duplicate using Covidence software and a senior reviewer resolved all author conflicts. We analyzed data descriptively. We included 193 published and 80 ongoing studies. Thirty-seven percent of included studies were systematic reviews. Only 12% of included studies were randomized controlled trials. The median number of participants was 22 with a median of 18 participants who had taken psilocybin. Thirty-eight percent of studies reported at least one potential conflict of interest. The most common indication was depression (28%). Also commonly studied were substance use (14%), mental health in life-threatening illness (9%), headaches (6%), depression and anxiety (6%), obsessive-compulsive disorder (3%), and anxiety disorders (3%). Most studies involving the administration of psilocybin have small sample sizes and the most common focus has been psychiatric disorders. There is a need for high-quality randomized trials on psilocybin and to expand consideration to other promising indications, such as chronic pain.

Sections du résumé

BACKGROUND UNASSIGNED
Psychedelic drugs have been of interest in medicine since the early 1950s. There has recently been a resurgence of interest in psychedelics.
AIMS UNASSIGNED
The objective of this study is to determine the extent of the available literature on psilocybin for medical indications including the designs used, study characteristics, indications studied, doses, and authors' conclusions. We identify areas for further study where there are research gaps.
METHODS UNASSIGNED
We conducted a systematic scoping review of clinical indications for psilocybin, encompassing psychiatric and medical conditions. We systematically searched Medline and Embase using keywords related to psilocybin. We reviewed titles and texts in duplicate using Covidence software. We extracted data individually in duplicate using Covidence software and a senior reviewer resolved all author conflicts. We analyzed data descriptively.
RESULTS UNASSIGNED
We included 193 published and 80 ongoing studies. Thirty-seven percent of included studies were systematic reviews. Only 12% of included studies were randomized controlled trials. The median number of participants was 22 with a median of 18 participants who had taken psilocybin. Thirty-eight percent of studies reported at least one potential conflict of interest. The most common indication was depression (28%). Also commonly studied were substance use (14%), mental health in life-threatening illness (9%), headaches (6%), depression and anxiety (6%), obsessive-compulsive disorder (3%), and anxiety disorders (3%).
CONCLUSIONS UNASSIGNED
Most studies involving the administration of psilocybin have small sample sizes and the most common focus has been psychiatric disorders. There is a need for high-quality randomized trials on psilocybin and to expand consideration to other promising indications, such as chronic pain.

Identifiants

DOI: 10.1177/02698811241269751 PMID: 39135496
pubmed: 39135496
doi: 10.1177/02698811241269751
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2698811241269751

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Kim Madden (K)

Research Institute of St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Department of Surgery, McMaster University, Hamilton, ON, Canada.
Department of Health Research Methods, McMaster University, Hamilton, ON, Canada.
Michael G. DeGroote Center for Medicinal Cannabis Research, McMaster University, Hamilton, ON, Canada.
ORCID: 0000-0002-2861-9636

Breanne Flood (B)

Research Institute of St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Department of Health Research Methods, McMaster University, Hamilton, ON, Canada.

Darren Young Shing (D)

Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

Michael Ade-Conde (M)

Royal College of Surgeons of Ireland, Dublin, Ireland.

Imad Kashir (I)

Research Institute of St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.

Melanie Mark (M)

Research Institute of St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.

James MacKillop (J)

Research Institute of St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Michael G. DeGroote Center for Medicinal Cannabis Research, McMaster University, Hamilton, ON, Canada.
Department of Psychiatry and Behavioral Neuroscience, McMaster University, Hamilton, ON, Canada.
Peter Boris Center for Addiction Research, McMaster University, Hamilton, ON, Canada.

Mohit Bhandari (M)

Department of Surgery, McMaster University, Hamilton, ON, Canada.
Department of Health Research Methods, McMaster University, Hamilton, ON, Canada.
Michael G. DeGroote Center for Medicinal Cannabis Research, McMaster University, Hamilton, ON, Canada.

Anthony Adili (A)

Research Institute of St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
Department of Surgery, McMaster University, Hamilton, ON, Canada.
Michael G. DeGroote Center for Medicinal Cannabis Research, McMaster University, Hamilton, ON, Canada.

Classifications MeSH